The committee normally gathers every three months but the WHO said the director-general pulled the meeting forward "to consider issues that need urgent discussion."
"These are the recent variants and considerations on the use [of] vaccination and testing certificates for international travel," the global body said Wednesday.
Mutations to Sars-CoV-2 are raising concerns among scientists who are scrambling to work out if they will respond to vaccines.
In particular, one mutation, detected initially in South Africa and on subsequent variants in Brazil and Japan, has raised alarm among researchers, who are studying the variant, known as 501Y.V2 to determine whether current vaccines will be effective.
Experts say the vaccines will very likely still work against the new variants. Studies to confirm are ongoing, but those experiments take time.
Professor of infectious diseases at the University of Cape Town, Marc Mendelson, told ABC News that it remains undetermined whether the South African variant is really more contagious. "Studies to date suggest that people infected with this variant have an increase in the viral load, which is likely to increase the ability of that person to transmit to others. The evidence is supported by the speed of increase numbers being infected during the second wave, both in South Africa and in the U.K., which has a separate variant which also carries the same mutation at position 501 in the spike protein," Mendelson, who is also the head of the Division of Infectious Diseases and HIV Medicine at Cape Town's Groote Schuur Hospital, told ABC News.
Mendelson said a lot of urgent work is underway to study the mutation and he's hopeful that some answers will be forthcoming within the next few weeks. "The most pressing question is around whether the mutations in the variant will affect vaccine responses. Then there's the question of whether the variant is associated with more severe disease? I am not seeing evidence of that on the ground (at my hospital), but subtle differences need a lot of data to pick it up, so that is anecdotal evidence. However at present, there is no signal that it causes more severe disease."
A preliminary study found that the Pfizer COVID-19 vaccine appears to work against the mutated virus, but more studies are needed because the South African variant has a number of additional mutations, including changes to some to the virus' spike protein.
According to Mendelson, the spike protein is not only vital for entry of the virus, but is also the site targeted by antibodies humans produce to control the viral infection. "Put simply, these antibodies neutralize the virus by binding to specific sequences of the spike protein, preventing it binding to a receptor on our cells and therefore preventing entry. If you can prevent entry of the virus into cells, you can prevent it replicating and inhibit it from causing an infection. The reason for concern is once again, a number of mutations in the genetic code of the virus that the variant has. The resulting changes in structure of the spike protein, could reduce the binding of antibodies to their recognition sites and therefore reduce the ability of our immune system to prevent the virus from entering cells and taking hold."
According to the WHO, the South African identified strain has been found in 20 countries, territories and areas after first being reported to the WHO on Dec. 18.
"From preliminary and ongoing investigations in South Africa, it is possible that the 501Y.V2 variant is more transmissible than variants circulating in South Africa previously," the agency's weekly report said.
"Moreover, while this new variant does not appear to cause more severe illness, the observed rapid increases in case numbers has placed health systems under pressure."The geographical spread of both variants is likely underestimated, said the WHO.
Fears over the increased transmissibility of the new variants are prompting fresh lockdowns and extra measures to contain COVID-19.
The South African strain is causing more concern, however, due to an additional mutation that has scientists on edge, one named E484K, which may render certain vaccines less effective.
The WHO also noted that a third new coronavirus variant "of concern," found in Japan, needs further investigation.
"The more the SARS-CoV-2 virus spreads, the more opportunities it has to change. High levels of transmission mean that we should expect more variants to emerge," the WHO stated.SARS-CoV-2 is the virus that causes COVID-19 disease. Viruses constantly undergo minor changes as they spread from person to person.
More than 90 million COVID-19 infections have been recorded globally since cases first appeared in December 2019. The death toll from the pandemic is nearing two million people.